Syndax Pharmaceuticals, Inc. (SNDX) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
35 Gatehouse Drive
New York City, MA 02451
United States of America (the)
Phone
781 419 1400
Website
Sector
Healthcare
Industry
Biotechnology
Employees
270
First IPO Date
March 02, 2016
| Name | Title | Pay | Year Born |
| Michael A. Metzger | Chief Executive Officer & Director | 1.61M | 1971 |
| Steven Closter | Chief Commercial Officer | 822,878 | 1969 |
| Luke J. Albrecht | Senior Vice President, General Counsel & Secretary | 842,308 | 1979 |
| Keith Alan Goldan | CFO, Treasurer & Principal Accounting Officer | 852,548 | 1971 |
| Nicholas Botwood MBBS | Head of Research & Development and Chief Medical Officer | 876,846 | 1968 |
| Michael Downes | Co-Founder | 0 | N/A |
| Peter Ordentlich | Co-Founder & Chief Scientific Officer | 0 | 1969 |
| Ronald Evans | Co-Founder, Advisor and Chair of Scientific Advisory Board | 0 | 1950 |
| Kevin McManus | Chief People Officer | 0 | 1969 |
| Sharon Klahre | Vice President of Investor Relations & Communications | 0 | N/A |
| Richard A. Heyman | Co-Founder | 0 | 1957 |
Syndax Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm focused on developing innovative therapies for cancer. Among its leading investigational products are SNDX-5613, currently undergoing Phase 1/2 clinical assessment, which targets the Menin-mixed lineage leukemia 1 protein interaction for treating MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML). Another significant candidate is SNDX-6352, or axatilimab, a monoclonal antibody designed to block the colony stimulating factor 1 (CSF-1) receptor, intended for patients suffering from chronic graft versus host disease (cGVHD). The company is additionally progressing Entinostat. Syndax has also established strategic collaborations, including a research and development agreement with the National Cancer Institute, a clinical trial agreement with the Eastern Cooperative Oncology Group, and a license agreement with Kyowa Hakko Kirin Co., Ltd. Founded in 2005, Syndax Pharmaceuticals, Inc. maintains its corporate headquarters in Waltham, Massachusetts.